Literature DB >> 2060533

Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia.

B Ruf1, I Rohde, H D Pohle.   

Abstract

Mild to moderately severe Pneumocystis carinii pneumonia in patients with AIDS was treated in a clinical trial with a combination regimen of primaquine and clindamycin, and the efficacy of this regimen was compared with that of the conventional treatment regimen of trimethoprim/sulfamethoxazole. The results revealed that primaquine/clindamycin appears to be an equally effective alternative to trimethoprim/sulfamethoxazole. The spectrum of side-effects was similar for the two regimens; side-effects occurred with equal frequency but appeared to be less severe in patients given primaquine/clindamycin. Because therapy with primaquine and clindamycin was limited to patients with mild to moderate Pneumocystis carinii pneumonia, studies with this regimen in more severe cases are warranted.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060533     DOI: 10.1007/bf01964466

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Clindamycin/primaquine for Pneumocystis carinii pneumonia.

Authors:  B Ruf; H D Pohle
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

Review 2.  Pneumocystis carinii pneumonia: therapy and prophylaxis.

Authors:  J A Kovacs; H Masur
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

3.  Effect of clindamycin on acute and chronic toxoplasmosis in mice.

Authors:  F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

4.  Clindamycin with primaquine for Pneumocystis carinii pneumonia.

Authors:  E Toma; S Fournier; M Poisson; R Morisset; D Phaneuf; C Vega
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

Review 5.  Recent advances in the diagnosis, treatment, and prevention of Pneumocystis carinii pneumonia.

Authors:  R T Davey; H Masur
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

6.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

7.  Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

Authors:  J A Kovacs; J W Hiemenz; A M Macher; D Stover; H W Murray; J Shelhamer; H C Lane; C Urmacher; C Honig; D L Longo
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

Review 8.  Pneumocystis carinii pneumonia and its treatment in patients with AIDS.

Authors:  B G Gazzard
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

  8 in total
  3 in total

Review 1.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

2.  8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; M Nasr; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

3.  Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia.

Authors:  Tark Kim; Heungsup Sung; Yong Pil Chong; Sung Han Kim; Eun Ju Choo; Sang Ho Choi; Tae Hyong Kim; Jun Hee Woo; Yang Soo Kim; Sang Oh Lee
Journal:  Infect Chemother       Date:  2018-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.